Collegium Pharmaceutical, Inc. (COLL) Analyse boursière

Présentation de l'entreprise

Collegium Pharmaceutical, Inc. operates within the healthcare sector, specifically focusing on the development and commercialization of prescription medicines designed for pain management. The company specializes in the pharmaceutical industry, targeting niche markets within drug manufacturing that cater to specialty and generic needs. With a market capitalization of $1.08 billion and annual revenue of $780.57 million, the firm demonstrates a substantial presence in its field, supported by a workforce of 423 employees. These valuation and revenue figures indicate that Collegium holds a significant position in the specialty pharmaceutical landscape, reflecting investor confidence in its pipeline and operational capabilities despite the capital-intensive nature of drug development.

Santé financière

The company reported trailing twelve-month revenue of $780.57 million, generating a net income of $62.87 million and an EBITDA of $419.16 million. The substantial gap between the revenue figure and the net income highlights a cost structure where operating expenses, including cost of goods sold and administrative costs, absorb approximately 91.9% of total revenue before reaching the bottom line. Free cash flow stands at $321.54 million, which provides the organization with considerable financial flexibility to fund research initiatives, manage working capital, or pursue strategic acquisitions without immediate reliance on external financing. Gross margin is reported at 88.5%, indicating high pricing power and low variable costs typical of pharmaceutical products; operating margin reaches 30.0%, demonstrating effective cost control over operations; and profit margin sits at 8.1%, reflecting the impact of general and administrative expenses on final profitability. In terms of leverage, total cash holdings of $386.68 million are contrasted against total debt of $936.43 million, resulting in a debt-to-equity ratio of 310.41%, which suggests a leveraged balance sheet structure rather than a conservative one. The current ratio is 1.57, signaling that the company possesses sufficient current assets to cover its short-term liabilities with a comfortable margin of safety. Return on equity is 23.7% and return on assets is 7.3%, metrics that reveal management's effectiveness in generating returns from shareholders' equity and utilizing the asset base to produce earnings.

Évaluation de la valorisation

The trailing twelve-month P/E ratio is 19.32, while the forward P/E ratio is significantly lower at 5.23. This disparity implies that the market expects earnings to grow substantially in the future, as the forward multiple is priced on anticipated higher profitability rather than current historical performance. The price-to-book ratio stands at 3.51, indicating that the market values the company at a significant premium over its tangible book value, likely due to the intangible assets associated with its drug portfolio and patent protections. Alternative valuation metrics such as the price-to-sales ratio of 1.39 and the EV/EBITDA of 3.84 offer different perspectives on value, suggesting the company trades at a moderate multiple relative to its sales and earnings power adjusted for enterprise value. The stock's 52-week range spans from a low of $23.23 to a high of $50.79, providing a historical volatility context for current pricing decisions relative to recent market extremes. The beta value is 0.77, which indicates that the stock's price volatility is lower than the broader market, suggesting it may be less sensitive to general market swings compared to large-cap peers.

Growth & Income

Revenue growth over the last year is 12.9%, while earnings growth reaches 31.5%, showing that profitability is expanding at a rate nearly three times faster than top-line sales. This divergence implies that the company is successfully leveraging its revenue base to improve operational efficiency or that one-time gains are contributing disproportionately to the earnings figure in the current period. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning it reinvests all available earnings back into business growth, research, and development rather than distributing cash to shareholders. The overall growth and income profile is characterized by strong earnings acceleration that outpaces revenue expansion, combined with a strategy of retaining capital to fuel future commercialization efforts within the pain management sector.